Page last updated: 2024-10-14

chromopyrrolic acid

Description

chromopyrrolic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

chromopyrrolic acid : A pyrroledicarboxylic acid that is pyrrole-2,5-dicarboxylic acid in which the hydrogens at positions 3 and 4 have been replaced by indol-3-yl groups. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID11326613
CHEMBL ID491841
CHEBI ID41625
SCHEMBL ID12955978
MeSH IDM0537006

Synonyms (16)

Synonym
chromopyrrolic acid
3,4-di-1h-indol-3-yl-1h-pyrrole-2,5-dicarboxylic acid
DB07588
lycogalic acid a
CHEMBL491841
bdbm50378456
lycogaric acid a
150044-68-1
1h-pyrrole-2,5-dicarboxylic acid, 3,4-di-1h-indol-3-yl-
SCHEMBL12955978
DTXSID90462496
C21125
CHEBI:41625
3,4-di(1h-indol-3-yl)-1h-pyrrole-2,5-dicarboxylic acid
3,4-di(indol-3-yl)pyrrole-2,5-dicarboxylic acid
Q27096807
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
bacterial metaboliteAny prokaryotic metabolite produced during a metabolic reaction in bacteria.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
indolesAny compound containing an indole skeleton.
pyrroledicarboxylic acidA pyrrole compound having two carboxy substituents at any position on the ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transcription factor HES-1Mus musculus (house mouse)IC50 (µMol)6.00006.00006.00006.0000AID447680
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
nucleoplasmTranscription factor HES-1Mus musculus (house mouse)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID447683Inhibition of mouse Hes1-mediated suppression of basic helix-loop-helix activator genes in C3H10T1/2 cells at 50 uM by luciferase transactivation assay2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
The first Hes1 dimer inhibitors from natural products.
AID447680Inhibition of Cy3-labeled mouse recombinant Hes1 (3-281) dimer formation expressed in Escherichia coli by microplate-based assay2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
The first Hes1 dimer inhibitors from natural products.
AID391903Antiviral activity against HSV2008Journal of natural products, Oct, Volume: 71, Issue:10
Lynamicins A-E, chlorinated bisindole pyrrole antibiotics from a novel marine actinomycete.
AID447682Inhibition of mouse Hes1-mediated suppression of basic helix-loop-helix activator genes in C3H10T1/2 cells by luciferase transactivation assay2009Bioorganic & medicinal chemistry letters, Oct-01, Volume: 19, Issue:19
The first Hes1 dimer inhibitors from natural products.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (57.14)29.6817
2010's3 (42.86)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]